Page last updated: 2024-11-05

1-hydroxypyrene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-Hydroxypyrene (1-OHP) is a polycyclic aromatic hydrocarbon (PAH) metabolite that is formed in the liver by cytochrome P450 enzymes. It is a potent mutagen and carcinogen, and is found in the environment as a result of incomplete combustion of organic materials. 1-OHP has been shown to induce DNA damage and cell death in various cell types. It is also known to inhibit the activity of certain enzymes involved in detoxification pathways. 1-OHP is studied because it is a biomarker of exposure to PAHs and its presence in biological samples can be used to assess the risk of cancer and other health problems. 1-OHP has been studied in relation to the development of lung cancer, bladder cancer, and skin cancer. Research on 1-OHP is important for understanding the mechanisms of PAH-induced toxicity and for developing strategies to prevent and treat PAH-related diseases.'

1-hydroxypyrene: pyrene metabolite; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21387
CHEMBL ID3184813
CHEBI ID34093
SCHEMBL ID218996
MeSH IDM0103001

Synonyms (45)

Synonym
BIDD:ER0523
BIDD:GT0133
1-hydroxy pyrene
nsc-30968
1-pyrenol
1-hydroxypyrene
5315-79-7
3-hydroxypyrene
nsc30968
pyren-1-ol
1-hydroxypyrene, 98%
nsc 30968
pyren-1-ol;1-hydroxypyrene1-pyrenol
A24650
NCGC00248108-01
pyrenol
hydroxypyrene
63021-84-1
tox21_300617
dtxsid1038298 ,
dtxcid9018298
NCGC00254432-01
cas-5315-79-7
unii-n2h6o5v707
n2h6o5v707 ,
FT-0670072
FT-0607935
AM20040642
AKOS015905692
SCHEMBL218996
H1435
CHEBI:34093 ,
1-hydroxypyrene, certified reference material, tracecert(r)
CHEMBL3184813
mfcd00044543
1-pyrenol; 1-hydroxypyrene; 3-hydroxypyrene; 3-pyrenol; nsc 30968
CS-W014791
SY045995
3-oxypyren
DS-14633
Q21099650
I10264
SB67012
HY-W014075
PD158310

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These data suggest that oxidative stress/DNA damage induced by PAHs may play a role in toxic responses for PAHs in immunological functions."( Lymphocyte oxidative stress/genotoxic effects are related to serum IgG and IgA levels in coke oven workers.
Chen, L; Gao, M; Kong, Y; Li, Y; Xue, X; Zheng, A, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
"The interactions of pyrene (Pyr) and/or 1-hydroxypyrene (1-OHPyr) with bovine serum albumin (BSA) in binary and ternary systems were investigated using the excitation-emission matrix (EEM)-parallel factor analysis (PARAFAC) method combined with fluorescence quenching analysis and the molecular docking method."( Interactions of pyrene and/or 1-hydroxypyrene with bovine serum albumin based on EEM-PARAFAC combined with molecular docking.
Chen, L; Liu, D; Zhang, J; Zhang, Y; Zhu, Y, 2018
)
1.04
" We investigated the effects of PAHs exposure combined with HR-HPV infection on CIN in community population in Shanxi Province, China."( Effects of exposure to polycyclic aromatic hydrocarbons combined with high-risk human papillomavirus infection on cervical intraepithelial neoplasia: A population study in Shanxi Province, China.
Ding, L; Gao, W; Li, X; Song, L; Wang, J; Wang, L, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" In addition, the bioavailability of chemical components of MGP were also investigated by monitoring polycyclic aromatic hydrocarbon (PAH) metabolites in urine and DNA adduct formation in forestomach and lung tissue."( Biochemical effects of manufactured gas plant residue following ingestion by B6C3F1 mice.
Goldstein, L; Patel, S; Weyand, EH; Wu, Y, 1994
)
0.29
" A significant increase in the bioavailability of pyrene after treatment with other PAHs was observed."( Effect of polycyclic aromatic hydrocarbons on the elimination kinetics of pyrene and the urinary excretion profile of 1-hydroxypyrene in the rat.
Lipniak-Gawlik, M, 1998
)
0.51
"Humic substances may influence the bioavailability of polycyclic aromatic hydrocarbons (PAHs) in aquatic environment."( Humic substances modify accumulation but not biotransformation of pyrene in salmon yolk-sac fry.
Honkanen, JO; Kukkonen, JV; Wiegand, C, 2008
)
0.35
" Biomarkers for uptake, bioavailability and bioactivation of PAH were lower in patients compared to volunteers."( DNA adducts in skin biopsies and 1-hydroxypyrene in urine of psoriasis patients and healthy volunteers following treatment with coal tar.
Aben, KK; Anzion, R; Dettbarn, G; Godschalk, R; Golsteijn, L; Kiemeney, LA; Roelofzen, JH; Scheepers, PT; Seidel, A; van der Valk, PG; van Schooten, FJ, 2012
)
0.66
" Overall, this study provides advanced mechanistic insights into the bioavailability of PYR and underlines a key role of the human small intestinal epithelium for the first pass metabolism of contaminants in food."( Polycyclic aromatic hydrocarbons in food--efflux of the conjugated biomarker 1-hydroxypyrene is mediated by Breast Cancer Resistance Protein (ABCG2) in human intestinal Caco-2 cells.
Hessel, S; Lampen, A; Seidel, A, 2013
)
0.62

Dosage Studied

1-hydroxypyrene (1-OHP) had significant dose-response relationships with increased TL decline. Dose-response relations between total PAH, pyrene, carcinogenic PAHs, and 1-hydrupyrene for smokers, and polycyclic aromatic hydrocarbons for non-smokers are suggested.

ExcerptRelevanceReference
" However, the dose-response of adverse health effects using biological exposure indices and biological limit values are rarely available."( Biological exposure limit for occupational exposure to coal tar pitch volatiles at cokeovens.
Jongeneelen, FJ, 1992
)
0.28
" Dose-response relations between total PAH, pyrene, carcinogenic PAHs, and 1-hydroxypyrene for smokers, and polycyclic aromatic hydrocarbons adsorbed to dust for non-smokers are suggested."( Exposure of iron foundry workers to polycyclic aromatic hydrocarbons: benzo(a)pyrene-albumin adducts and 1-hydroxypyrene as biomarkers for exposure.
Autrup, H; Hansen, AM; Omland, O; Overgaard, E; Sherson, D; Sigsgaard, T, 1994
)
0.73
" Furthermore, the time course of 1-OHP excretion in either bile or urine following intravenous dosing resembled that observed after oral administration."( Urinary and biliary excretion kinetics of 1-hydroxypyrene following intravenous and oral administration of pyrene in rats.
Bouchard, M; Viau, C, 1998
)
0.56
" Groups of male Wistar rats were dosed with pyrene and with mixture of pyrene and fluoranthene, pyrene and benz[a]anthracene, or pyrene, fluoranthene, and benz[a]anthracene at 20 mg/kg by intravenous or oral routes."( Effect of polycyclic aromatic hydrocarbons on the elimination kinetics of pyrene and the urinary excretion profile of 1-hydroxypyrene in the rat.
Lipniak-Gawlik, M, 1998
)
0.51
"Highly significant differences and dose-response relationships with regard to cigarettes smoked per day were found for 2-, 3- and 4-hydroxyphenanthrene and 1-hydroxypyrene, but not for 1-hydroxyphenanthrene."( Urinary monohydroxylated phenanthrenes and hydroxypyrene--the effects of smoking habits and changes induced by smoking on monooxygenase-mediated metabolism.
Angerer, J; Heudorf, U, 2001
)
0.51
" Moreover, 3,4-oxidation of phenanthrenes was found to be enhanced in smokers, with a significant dose-response relationship."( Urinary monohydroxylated phenanthrenes and hydroxypyrene--the effects of smoking habits and changes induced by smoking on monooxygenase-mediated metabolism.
Angerer, J; Heudorf, U, 2001
)
0.31
" Biological monitoring was performed through dosing of 1-hydroxypyrene (pyrene metabolite) in urine samples taken at the end of each workshift."( Assessment of exposure to polycyclic aromatic hydrocarbons in police in Florence, Italy, through personal air sampling and biological monitoring of the urinary metabolite 1-hydroxypyrene.
Bavazzano, P; Boddi, V; Gottardi, M; Lanciotti, E; Perico, A,
)
0.57
"08) than did controls, and dose-response relationships were also found between external exposure (exposure category) or internal doses (urinary 1-hydroxypyrene) and DNA damage."( [Relationship of polycyclic aromatic hydrocarbon exposure with peripheral blood lymphocyte DNA damage in coke oven workers].
Dai, YF; Gu, YP; He, FS; Leng, SG; Li, T; Li, XH; Niu, Y; Pan, ZF; Wang, YW; Wang, ZX; Xiao, J; Zhang, WZ; Zheng, YX, 2004
)
0.52
"There are dose-effect and dose-response relationships between PAHs exposure and lymphocyte DNA damage in coke oven workers."( [Relationship of polycyclic aromatic hydrocarbon exposure with peripheral blood lymphocyte DNA damage in coke oven workers].
Dai, YF; Gu, YP; He, FS; Leng, SG; Li, T; Li, XH; Niu, Y; Pan, ZF; Wang, YW; Wang, ZX; Xiao, J; Zhang, WZ; Zheng, YX, 2004
)
0.32
" It was concluded that under controlled study conditions: (1) 1-OHP, S-PMA and t,t-MA are useful biomarkers that could differentiate exposure between smoking conventional and EHCSS cigarettes or between smoking conventional cigarettes and no smoking; between S-PMA and t,t-MA, the former appeared to be more sensitive; (2) 3-MeAd could only differentiate between smoking conventional cigarettes and no smoking; the results for 3-EtAd were not conclusive because contradictory results were observed; (3) 8-OHdG had a questionable association with smoking and therefore the utility of this biomarker for smoking-related exposure could not be established; and (4) urinary excretion of thioethers as a biomarker lacked sensitivity to demonstrate a clear dose-response relationship in conventional cigarette smokers, although it could differentiate the excretion levels between those subjects who smoked a conventional cigarette and those who stopped smoking."( Evaluation of urinary 1-hydroxypyrene, S-phenylmercapturic acid, trans,trans-muconic acid, 3-methyladenine, 3-ethyladenine, 8-hydroxy-2'-deoxyguanosine and thioethers as biomarkers of exposure to cigarette smoke.
Engl, J; Feng, S; Jin, Y; Kinser, R; Liang, Q; Riedel, K; Roethig, HJ; Scherer, G; Urban, M,
)
0.45
" Specific IgE dosage and skin prick tests were done on 18 workers giving altered values of spirometry or anamnestic allergic symptoms."( Biological monitoring and allergic sensitization in traffic police officers exposed to urban air pollution.
Assennato, G; Bellotta, MR; Bisceglia, L; Carrus, A; Daprile, C; Di Leo, E; Martina, G; Nettis, E; Russo, A; Tatò, I; Vimercati, L,
)
0.13
" The aim of this study was to investigate, the possible correlation between occupational exposition to polycyclic aromatic hydrocarbons (PAHs) generated from incomplete combustion, by dosage of urinary 1-hydroxypyrene (1-OHP u) as biomarker of internal dose for polycyclic aromatic hydrocarbons."( [Urinary 1-OHP excretion of urban traffic exhausts exposed workers].
Cazzato, RG; d'Ettorre, G; De Giorgio, N; Mazzotta, M,
)
0.32
" Induction kinetics were calculated using a logistic-like model and approximate dose-response curves were designed."( EROD activity in peripheral blood lymphocytes and 1-hydroxypyrene in urine and milk as biomarkers of PAH exposure in dairy ruminants.
Chahin, A; Dziurla, MA; Guiavarc'h, YP; Jondreville, C; Rychen, G; Yen, FT, 2011
)
0.62
"Polycyclic aromatic hydrocarbons (PAHs) are known to induce reactive oxygen species and oxidative stress, but the dose-response relationships between exposure to PAHs and oxidative stress levels have not been established."( Dose-response relationships of polycyclic aromatic hydrocarbons exposure and oxidative damage to DNA and lipid in coke oven workers.
Deng, Q; Guan, L; Guo, H; Hu, D; Huang, K; Kuang, D; Wu, T; Zhang, W; Zhang, X, 2013
)
0.39
" When an exposure metric is used that is fairly new, epidemiology does not offer dose-response data that is needed for the derivation of a science based limit value."( A guidance value of 1-hydroxypyrene in urine in view of acceptable occupational exposure to polycyclic aromatic hydrocarbons.
Jongeneelen, FJ, 2014
)
0.73
" We found that the urinary level of 1-hydroxypyrene (1-OHP) had significant dose-response relationships with increased TL decline [β(95%CI) = 0."( The interaction effects of polycyclic aromatic hydrocarbons exposure and TERT- CLPTM1L variants on longitudinal telomere length shortening: A prospective cohort study.
Bai, Y; Chen, W; Chen, Z; Fu, W; Guo, H; He, M; Li, G; Li, X; Wang, G; Wang, S; Wu, T; Wu, X; Zhang, X, 2018
)
0.76
"We found decreased dose-response of white blood cells, eosinophils, monocytes and lymphocytes with increased PAHs exposure in two consecutive years."( Polycyclic aromatic hydrocarbons exposure and hematotoxicity in occupational population: A two-year follow-up study.
Chen, W; Dai, Y; Duan, H; Gao, A; Ji, Q; Jia, Q; Li, Y; Liu, X; Niu, Y; Su, W; Sun, J; Wang, Q; Wang, T; Wang, W; Wang, Y; Yao, H; Zhao, H; Zhi, Q; Zhu, X, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrenes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency79.64070.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency16.26520.006038.004119,952.5996AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency24.82240.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency14.39190.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency38.93700.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency27.30600.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency61.64480.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency44.53460.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency24.54120.000817.505159.3239AID1159527
farnesoid X nuclear receptorHomo sapiens (human)Potency43.64120.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency27.30600.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency39.24180.000229.305416,493.5996AID743069; AID743075; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency35.21500.001024.504861.6448AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency21.87240.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency38.89520.023723.228263.5986AID743222; AID743241
aryl hydrocarbon receptorHomo sapiens (human)Potency17.01250.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency54.48270.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency58.29290.143427.612159.8106AID1159516; AID1159519
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency34.23000.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency89.76250.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency52.20380.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency54.94100.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency36.44710.000627.21521,122.0200AID743202; AID743219
Cellular tumor antigen p53Homo sapiens (human)Potency54.48270.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (567)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (1.94)18.7374
1990's123 (21.69)18.2507
2000's203 (35.80)29.6817
2010's207 (36.51)24.3611
2020's23 (4.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.86 (24.57)
Research Supply Index6.44 (2.92)
Research Growth Index5.60 (4.65)
Search Engine Demand Index48.04 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (2.96%)5.53%
Reviews18 (2.96%)6.00%
Case Studies1 (0.16%)4.05%
Observational0 (0.00%)0.25%
Other571 (93.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]